Literature DB >> 9451596

Selection of self-reactive peptides within human aggrecan by use of a HLA-DRB1*0401 peptide binding motif.

A M Boots1, G F Verheijden, R Schöningh, C J van Staveren, E Bos, D Elewaut, F de Keyser, E Veys, I Joosten, A W Rijnders.   

Abstract

The pathogenesis of joint destruction in rheumatoid arthritis remains ill-defined. Joint destruction is thought to be the result of tissue damage mediated by T cells. The mere presence of articular cartilage appears responsible for sustaining chronic synovitis and thereby forwards a role for cartilage-responsive T cells in RA. Taking advantage of the positive DRB1*0401 association with RA susceptibility, we reasoned that T-cell recognition of autoantigens in RA would be restricted by DRB1*0401-encoded molecules. A DR4 (B1*0401) peptide binding motif was used for the identification of putative T-cell epitopes within human aggrecan, a candidate autoantigen. Thirteen peptides were synthesized and tested for binding DRB1*0401 or 0404-encoded molecules. Selected binders were tested for induction of proliferative responses in peripheral blood mononuclear cells from donors carrying the DR4 or DR1 specificity. Both healthy and RA donors responded to human aggrecan-derived peptides, thereby identifying these sequences as T-cell epitopes. Interestingly, responses to aggrecan-derived epitopes were significantly decreased in RA patients compared to controls. This was not due to an overall hyporesponsiveness of RA patients since responses to a recall antigen or mitogen did not differ from controls. The data suggest that in RA, aggrecan-specific T cells may exist in a different stage of activation or may have left the periphery to home to the joint.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9451596     DOI: 10.1006/jaut.1997.0164

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  5 in total

1.  Citrullinated Aggrecan Epitopes as Targets of Autoreactive CD4+ T Cells in Patients With Rheumatoid Arthritis.

Authors:  Cliff Rims; Hannes Uchtenhagen; Mariana J Kaplan; Carmelo Carmona-Rivera; Philip Carlucci; Katalin Mikecz; Adrienn Markovics; Jeffrey Carlin; Jane H Buckner; Eddie A James
Journal:  Arthritis Rheumatol       Date:  2019-03-08       Impact factor: 10.995

2.  Intramolecular polyspecificity in CD4 T-cell recognition of Ad-restricted epitopes of proteoglycan aggrecan.

Authors:  Jane Falconer; Katie Lowes; Anna L Furmanski; Julian Dyson; Wan Fai Ng; John H Robinson
Journal:  Immunology       Date:  2014-05       Impact factor: 7.397

Review 3.  Humanized Mouse Models of Rheumatoid Arthritis for Studies on Immunopathogenesis and Preclinical Testing of Cell-Based Therapies.

Authors:  Katina Schinnerling; Carlos Rosas; Lilian Soto; Ranjeny Thomas; Juan Carlos Aguillón
Journal:  Front Immunol       Date:  2019-02-19       Impact factor: 7.561

Review 4.  Non-MHC risk alleles in rheumatoid arthritis and in the syntenic chromosome regions of corresponding animal models.

Authors:  Timea Besenyei; Andras Kadar; Beata Tryniszewska; Julia Kurko; Tibor A Rauch; Tibor T Glant; Katalin Mikecz; Zoltan Szekanecz
Journal:  Clin Dev Immunol       Date:  2012-12-06

5.  Identification of an altered peptide ligand based on the endogenously presented, rheumatoid arthritis-associated, human cartilage glycoprotein-39(263-275) epitope: an MHC anchor variant peptide for immune modulation.

Authors:  Annemieke M H Boots; Henk Hubers; Milou Kouwijzer; Leontien den Hoed-van Zandbrink; Bernice M Westrek-Esselink; Cindy van Doorn; Rachel Stenger; Ebo S Bos; Marie-jose C van Lierop; Gijs F Verheijden; Cornelis M Timmers; Catharina J van Staveren
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.